Mesoblast Ltd
MESO10.160USD
-0.275-2.64%
Cierre 06/23, 16:00（ET）Cotizaciones retrasadas 15 min
1.17BCap. mercado
PérdidaP/E TTM
Más Datos de Mesoblast Ltd Compañía
Mesoblast Limited is an Australia-based company, which is engaged in developing allogeneic (off-the-shelf) cellular medicines for the treatment of severe and life-threatening inflammatory conditions. It has leveraged its proprietary mesenchymal lineage cell therapy technology platform to establish a broad portfolio of late-stage product candidates. It is developing product candidates for distinct indications based on its remestemcel-L and rexlemestrocel-L allogeneic stromal cell technology platforms. Remestemcel-L is being developed for inflammatory diseases in children and adults including steroid refractory acute graft versus host disease, and biologic-resistant inflammatory bowel disease. Rexlemestrocel-L is being developed for advanced chronic heart failure (REVASCOR) and chronic low back pain (MPC-06-ID). Two products have been commercialized in Japan and Europe by the Company's licensees. It has established commercial partnerships in Europe and China for certain Phase III assets.
Información de la empresa
Símbolo de cotizaciónMESO
Nombre de la empresaMesoblast Ltd
Fecha de salida a bolsaDec 16, 2004
Fundada en2004
Director ejecutivoDr. Silviu Itescu
Número de empleados73
Tipo de seguridadDepository Receipt
Fin del año fiscalDec 16
DirecciónL 38 55 Collins St
CiudadMELBOURNE
Bolsa de valoresNASDAQ Global Select Consolidated
PaísAustralia
Código postal3000
Teléfono61396396036
Sitio Webhttps://www.mesoblast.com/
Símbolo de cotizaciónMESO
Fecha de salida a bolsaDec 16, 2004
Fundada en2004
Ejecutivos de la empresa
Nombre
Nombre/Posición
Posición
Accionistas
Cambio
Dr. Eric A. Rose, M.D.
Dr. Eric A. Rose, M.D.
Executive Director, Chief Medical Officer
Executive Director, Chief Medical Officer
41.16K
--
Dr. Fiona See, Ph.D.
Dr. Fiona See, Ph.D.
Senior Vice President, Head - Translational Research
Senior Vice President, Head - Translational Research
--
--
Mr. William M. (Bill) Burns
Mr. William M. (Bill) Burns
Non-Executive Independent Vice Chairman of the Board
Non-Executive Independent Vice Chairman of the Board
--
--
Mr. Philip R. Krause, M.D.
Mr. Philip R. Krause, M.D.
Non-Executive Independent Director
Non-Executive Independent Director
--
--
Mr. Paul Hughes
Mr. Paul Hughes
Joint Company Secretary
Joint Company Secretary
--
--
Dr. Fiona See, Ph.D.
Dr. Fiona See, Ph.D.
Senior Vice President, Head - Translational Research
Senior Vice President, Head - Translational Research
--
--
Mr. Philip J. (Phil) Facchina
Mr. Philip J. (Phil) Facchina
Non-Executive Independent Director
Non-Executive Independent Director
--
--
Ms. Niva Sivakumar
Ms. Niva Sivakumar
Joint Company Secretary
Joint Company Secretary
--
--
Mr. Paul Hughes
Mr. Paul Hughes
Joint Company Secretary
Joint Company Secretary
--
--
Ms. Niva Sivakumar
Ms. Niva Sivakumar
Joint Company Secretary
Joint Company Secretary
--
--
Ver más
Nombre
Nombre/Posición
Posición
Accionistas
Cambio
Dr. Eric A. Rose, M.D.
Dr. Eric A. Rose, M.D.
Executive Director, Chief Medical Officer
Executive Director, Chief Medical Officer
41.16K
--
Dr. Fiona See, Ph.D.
Dr. Fiona See, Ph.D.
Senior Vice President, Head - Translational Research
Senior Vice President, Head - Translational Research
--
--
Mr. William M. (Bill) Burns
Mr. William M. (Bill) Burns
Non-Executive Independent Vice Chairman of the Board
Non-Executive Independent Vice Chairman of the Board
--
--
Mr. Philip R. Krause, M.D.
Mr. Philip R. Krause, M.D.
Non-Executive Independent Director
Non-Executive Independent Director
--
--
Mr. Paul Hughes
Mr. Paul Hughes
Joint Company Secretary
Joint Company Secretary
--
--
Dr. Fiona See, Ph.D.
Dr. Fiona See, Ph.D.
Senior Vice President, Head - Translational Research
Senior Vice President, Head - Translational Research
--
--
Desglose de ingresos
Sin datos
Sin datos
Por negocio
Por región
Sin datos
Estadísticas de accionistas
Actualizado: sáb., 17 de may
Actualizado: sáb., 17 de may
Accionistas
Tipos de accionistas
Accionistas
Accionistas
Proporción
BlackRock Institutional Trust Company, N.A.
0.44%
Citadel Advisors LLC
0.38%
Morgan Stanley & Co. International Plc
0.25%
Susquehanna International Group, LLP
0.20%
Goldman Sachs & Company, Inc.
0.20%
Other
98.52%
Accionistas
Accionistas
Proporción
BlackRock Institutional Trust Company, N.A.
0.44%
Citadel Advisors LLC
0.38%
Morgan Stanley & Co. International Plc
0.25%
Susquehanna International Group, LLP
0.20%
Goldman Sachs & Company, Inc.
0.20%
Other
98.52%
Tipos de accionistas
Accionistas
Proporción
Investment Advisor
1.46%
Research Firm
0.99%
Hedge Fund
0.45%
Investment Advisor/Hedge Fund
0.20%
Individual Investor
0.06%
Other
96.83%
Participación institucional
Actualizado: mar., 4 de mar
Actualizado: mar., 4 de mar
Periodo del informe
Número de instituciones
Acciones mantenidas
Proporción
Cambio
2025Q1
121
3.21M
2.52%
-64.68K
2024Q4
122
3.23M
2.55%
+620.09K
2024Q3
100
1.76M
1.52%
-1.23M
2024Q2
98
1.70M
1.52%
-705.91K
2024Q1
97
1.24M
1.12%
-806.95K
2023Q4
94
840.17K
0.85%
-1.02M
2023Q3
97
766.21K
0.94%
-1.35M
2023Q2
99
982.29K
1.21%
-1.15M
2023Q1
103
1.33M
1.81%
-837.80K
2022Q4
108
1.43M
1.94%
-964.96K
Ver más
Actividad de los accionistas
Nombre
Acciones mantenidas
Proporción
Cambio
Cambio %
Fecha
BlackRock Institutional Trust Company, N.A.
584.29K
0.46%
+584.29K
--
Dec 31, 2024
Morgan Stanley & Co. International Plc
163.50K
0.13%
+163.50K
--
Dec 31, 2024
Susquehanna International Group, LLP
153.98K
0.12%
+37.24K
+31.90%
Dec 31, 2024
Morgan Stanley & Co. LLC
225.25K
0.18%
+54.27K
+31.74%
Dec 31, 2024
Summit Wealth Strategies
145.66K
0.11%
-2.04K
-1.38%
Dec 31, 2024
UBS Financial Services, Inc.
165.15K
0.13%
+165.15K
--
Dec 31, 2024
Ver más
ETFs relacionados
Actualizado: vie., 6 de jun
Actualizado: vie., 6 de jun
Nombre
Proporción
iShares Biotechnology ETF
0.09%
Invesco Nasdaq Biotechnology ETF
0.04%
ProShares Ultra Nasdaq Biotechnology
0.04%
ActivePassive International Equity ETF
0.01%
iShares Biotechnology ETF
Proporción0.09%
Invesco Nasdaq Biotechnology ETF
Proporción0.04%
ProShares Ultra Nasdaq Biotechnology
Proporción0.04%
ActivePassive International Equity ETF
Proporción0.01%
Dividendos
Un total de
0.00
USD se ha distribuido en dividendos durante los últimos 5 años.
Fecha
Dividendos
Fecha de registro
Fecha de pago
Fecha ex-dividendo
Sin datos
División de acciones
Fecha
Tipo
Relación
Dec 22, 2023
Merger
2<1
Dec 22, 2023
Merger
2<1
Dec 22, 2023
Merger
2<1
Dec 22, 2023
Merger
2<1
Fecha
Tipo
Relación
Dec 22, 2023
Merger
2<1
Dec 22, 2023
Merger
2<1
Dec 22, 2023
Merger
2<1
Dec 22, 2023
Merger
2<1
